https://www.selleckchem.com/pr....oducts/mps1-in-6-com
In recent years, psychedelic substances with serotonergic mechanisms have accumulated substantial evidence that they may provide therapeutic benefits forpeople suffering with psychiatric symptoms. Psychiatric disorders targeted by these psychedelic-assisted therapies are managed with serotonergic drugs likeselective serotonin reuptake inhibitors (SSRIs) as the current standard of care, so it is important to evaluate the potential risks of drug-drug interactions andserotonin toxicity (ST) between these agents. A critical ev
إعجاب
علق
شارك
